Although there is huge potential, I think this should be revisited later. Jon has mentioned it before, but the team already have their hands full, and the list of new indications which we know are rare diseases are going to increase that workload further even with preclinical/p2 preparations.
When/if we get acquired, I think our partner can re-look at TBI with NNZ-2591 with the lessons learnt of the Trof trial experience.
Ann: Final Director's Interest Notice - T Scott, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.96 |
Change
-0.140(1.07%) |
Mkt cap ! $1.612B | |||
| Open | High | Low | Value | Volume |
| $13.20 | $13.36 | $12.82 | $4.627M | 354.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7585 | $12.96 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.03 | 3344 | 2 |
View Market Depth
| Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |